Eli Lilly appoints Melissa Barnes as chief ethics and compliance officer

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it here each Friday.

Eli Lilly appoints Melissa Barnes as chief ethics and compliance officer

Eli Lilly ($LLY) named Melissa Barnes chief ethics and compliance officer and senior vice president of enterprise risk management. Barnes will replace Anne Nobles, who will retire at the end of the year. Barnes will start in her new role Jan. 1. She is now responsible for litigation, compliance and specialty legal areas, including regulatory and human resources. A graduate of Harvard Law School, Barnes joined the company in 1994 and has served in a number of legal and business positions at Lilly. "Melissa's legal background and extensive experience at Lilly make her the right person to assume this important role within our company," John Lechleiter, chairman, president and CEO, said. "Lilly is committed to conducting our business with the highest level of integrity and in full compliance with the laws and regulations that govern our operations. Having someone with Melissa's qualifications lead our ethics and compliance organization is evidence of this commitment." Release

Melissa Barnes--Eli Lilly

Barnes will serve as chief ethics and compliance officer.

Eric Smart--Coldstream Laboratories
Smart will serve as CEO.

Daniel Lynch--Nimbus Discovery
Lynch will serve as executive chairman of the Board of Directors.


> Nimbus Discovery appointed Daniel S. Lynch to the company's Board of Directors as executive chairman. Story

> Clearside Biomedical named Charles Deignan CFO. Release

> Sigma-Tau Pharmaceuticals appointed Jeff Hackman as vice president of commercial operations. Release

> Spectrum Pharmaceuticals ($SPPI) appointed former Amgen ($AMGN) executive Joseph Turgeon as senior vice president, sales and commercial operations. Release

> Pharmalink AB appointed Heather Cook as director of regulatory affairs and Marek Poszepczynski as director of business development. Release

> BioTime ($BTX) and its subsidiary OrthoCyte appointed Francois Binette as vice president. Release

Medical Devices

> HiberGene Diagnostics appointed Tony Hill as CEO. Story

> sBioMed announced Stephen P. MacMillan, former Stryker ($SYK) chairman and CEO, as CEO.  Release


> Watson Pharmaceuticals ($WPI) announced its global generics team: Andrew Boyer will lead the team; Jean-Guy Goulet will lead the Canada and Latin America businesses; Lars Ramneborn will lead the European generics business; Hordur Thorhallsson will lead Watson's Asia and Middle East and Africa generics businesses; Karen McTavish will lead the Australian business; Hafrun Fridriksdottir will lead the global generics R&D function; Stefan Sveinsson will lead the specialty pharmaceutical development function; Wolter F. Kuizinga will lead the international business development function; and Daniel N. Motto will lead the U.S. business development function. Release

Pharma Manufacturing

> Patheon announced Michael Lehmann joined the company as president of global pharmaceutical development services. Release

> Coldstream Laboratories named Eric Smart president and CEO. Release

Pharma Distribution

> AmerisourceBergen ($ABC) named Lawrence C. Marsh chief strategy officer and senior vice president of new market development. Release